⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Ionis reports third quarter 2025 financial results and highlights progress on key programs
businesswire.com
IONS
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
businesswire.com
IONS
Ionis to hold third quarter 2025 financial results webcast
businesswire.com
IONS
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
businesswire.com
IONS
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
businesswire.com
IONS
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
businesswire.com
IONS
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
businesswire.com
IONS
Ionis to host investors and analysts for Innovation Day 2025
businesswire.com
IONS